Cathie Wood Goes On A Massive Shopping Spree: Ark Adds Tesla, Palantir, Cerebras, Amazon And Alphabet To

Ark increased its Tesla stake as the article ties the move to ongoing scrutiny of Tesla’s Full Self-Driving after a Texas crash.

Likely limited near-term impact; any effect would be sentiment/flow rather than a fresh fundamental catalyst.

The only concrete items are Ark’s share purchases and a reference to existing FSD scrutiny; no new Tesla filing, ruling, or technical change is disclosed.

Ark bought 25,795 shares of Cerebras Systems via ARKK/ARKW, totaling about $5.8M at a stated $226.72 close.

Modest support possible if traders treat Ark activity as a signal, but fundamental follow-through is not evidenced here.

A concrete trade size and price are provided, but there is no accompanying CBRS operational update (earnings, trial, contract, or guidance).

The headline claims Ark added Palantir, but the body does not provide a specific Palantir trade size, price, or new Palantir event.

No clear tradable edge from this text alone.

Unlike CBRS/GOOG/CRWV, the Palantir section is not supported with the same level of disclosed specifics in the provided body.

Ark’s Amazon buying is discussed alongside an FTC probe into advertising practices and concerns about consumer spending, plus AWS growth.

Potentially mixed; flows may support, while regulatory/consumer concerns cap upside absent new filings.

It references an FTC probe and AWS growth, but the newest concrete disclosure is Ark’s general buying framing rather than a new AMZN catalyst.

Ark purchased 23,603 Alphabet Class C shares via ARKK/ARKW, about $8.2M at a stated $346.08 close.

Small-to-moderate sentiment support possible, but unlikely to drive a sustained move without new Alphabet fundamentals.

The trade size and price are concrete, yet the article’s additional Alphabet context (Dow inclusion) is not a new fundamental driver.

Ark bought 76,195 shares of CoreWeave via ARKK/ARKW, about $8.1M at a stated $105.72 close.

Near-term flow/sentiment tailwind possible; fundamental repricing would require additional CRWV-specific news not present in the text.

The transaction details are specific, but the supporting catalysts are described generally as 'recent performance' rather than newly reported facts.

Ark sold 327,053 shares of Roku through ARKK/ARKW/ARKF, but the article provides no Roku-specific new development.

Could weigh on sentiment at the margin, but likely limited without new Roku news.

The trade size is provided, yet the article does not disclose why Roku was sold (no earnings, guidance, or regulatory event).

Ark sold 130,391 shares of Strata Critical Medical (SRTA) via ARKQ/ARKX, with no accompanying SRTA news.

Potential short-term negative sentiment from flow, but low conviction on price impact.

The transaction is concrete, but the absence of a new SRTA catalyst reduces tradable informational value.